NCT04301895

Brief Summary

Volunteers will receive a weight-based opioid (remifentanil) infusion for 10 minutes. In the first run, serial pupillary measurements (pupillary unrest, pupil diameter) will be taken at baseline, and at 2.5-minute intervals during the infusion and a 25-minute recovery period afterwards. After a washout period, the experiment will be repeated in each subject (second run). The two runs differ only by presence versus absence of verbal interaction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Apr 2019

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 30, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 3, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 3, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 3, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 10, 2020

Completed
Last Updated

March 10, 2020

Status Verified

March 1, 2020

Enrollment Period

4 months

First QC Date

March 3, 2020

Last Update Submit

March 5, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Impact of environmental stimulation on decline in oxygen saturation to ≤ 90%.

    Conversational interaction and oxygen saturation measured by pulse oximeter.

    35 minutes

  • Impact of environmental stimulation on CO2 increase of 15% or more above baseline.

    Conversational interaction and CO2 measured by transcutaneous sensor.

    35 minutes

  • Correlation between estimated opioid concentration and deviation in pupillary measurement.

    Relationship of opioid concentration to pupillary unrest, measured by the pupillometer

    35 minutes

Secondary Outcomes (1)

  • Impact of environmental stimulation on opioid-related deviations in pupillary measurements.

    35 minutes

Study Arms (2)

Interactive

OTHER

Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.

Behavioral: Continuous conversational interactionDrug: Remifentanil infusion

Non-interactive

OTHER

All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.

Drug: Remifentanil infusion

Interventions

Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.

Also known as: Environmental stimulation
Interactive

10 minute remifentanil infusion

InteractiveNon-interactive

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy
  • Able to provide informed consent

You may not qualify if:

  • Active substance use disorder
  • Prior opioid use disorder
  • Opioid use within 30 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California San Francisco

San Francisco, California, 94143, United States

Location

Related Publications (1)

  • McKay RE, Kohn MA, Larson MD. Pupillary unrest, opioid intensity, and the impact of environmental stimulation on respiratory depression. J Clin Monit Comput. 2022 Apr;36(2):473-482. doi: 10.1007/s10877-021-00675-3. Epub 2021 Mar 2.

MeSH Terms

Conditions

Acute PainOpiate OverdoseRespiratory Insufficiency

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsDrug OverdosePrescription Drug MisuseDrug MisuseSubstance-Related DisordersChemically-Induced DisordersOpioid-Related DisordersNarcotic-Related DisordersMental DisordersRespiration DisordersRespiratory Tract Diseases

Study Officials

  • Rachel Eshima McKay, M.D.

    Professor of Anesthesia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: Each subject is his/her own control.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 3, 2020

First Posted

March 10, 2020

Study Start

April 30, 2019

Primary Completion

September 3, 2019

Study Completion

September 3, 2019

Last Updated

March 10, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations